All In Biotech

Drug Trial Radar · NCT05522387

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

An Open Label Extension of XPro1595 in Patients With Alzheimer's Disease That Have Completed a Phase 1 or Phase 2 Study With XPro1595

Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

11

Actual

Start

Feb 21, 2023

Primary completion

Jun 5, 2024

Study completion Jul 5, 2024

Sponsor

Lead sponsor
Inmune Bio, Inc.Industry
Sponsor type
Industry
First posted
Aug 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 55 years, up to 86 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this Phase 2 Open Label study is to evaluate long-term safety, tolerability, and efficacy of XPro1595 on measures of cognition, function and brain quality in individuals with Alzheimer's Disease.

Conditions

  • Alzheimer Disease
  • Dementia
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Tauopathies
  • Neurodegenerative Diseases
  • Neurocognitive Disorders
  • Mental Disorders

Interventions

  • XPro1595Drug

    Each enrolled patient will be treated with 1.0 mg/kg of XPro1595 as a subcutaneous injection once a week for 55, or 74 weeks, for a total exposure to XPro1595 of up to 78 weeks (18 months), depending on their previous study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants who experience adverse events and serious adverse eventsTime frame: Weeks 55, or 74 in the OLE Study

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • KaRa MINDS

    Macquarie Park, New South Wales, Australia

  • Neuro Trials Victoria Pty Ltd T/A NeuroCentrix

    Carlton, Victoria, Australia

  • Austin Health

    Ivanhoe, Victoria, Australia

  • Australian Alzheimer's Research Foundation

    Perth, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.